Meeting report: 28th International Conference on Antiviral Research in Rome, Italy

• This article summarizes the principal invited lectures at the 28th International Conference on Antiviral Research.
• Phillip Furman, Elion award recipient, described research leading to the discovery of sofosbuvir.
• Dennis Liotta, Holý award recipient, described how an investigation into HIV entry inhibitors led to a new cancer therapy.
• Erica Ollmann Saphire, Prusoff award recipient, explored how viral proteins remodel for different roles in replication.
• Keynote talks focused on the treatment of HCV infection and on the role of Médicins Sans Frontières in the Ebola epidemic.

The 28th International Conference on Antiviral Research (ICAR) was held in Rome, Italy from May 11 to 15, 2015. This article summarizes the principal invited lectures. Phillip Furman, the Elion award recipient, described the research leading to sofosbuvir. Dennis Liotta, who received the Holý award, described how an investigation into HIV entry inhibitors led to a new therapy for cancer patients. Erica Ollmann Saphire, winner of the Prusoff Young Investigator award, explored the world of viral proteins and how they remodel to perform different essential roles in viral replication. The keynote addresses, by Raffaele De Francesco and Michael Manns, reported on the remarkable progress made in the therapy of chronic HCV infections. A third keynote address, by Armand Sprecher, related the difficulties and successes of Médicins Sans Frontières in West Africa ravaged by the Ebola outbreak. There were three mini-symposia on RNA Viruses, Antiviral Chemistry and Emerging Viruses. There was a good collection of talks on RNA viruses (norovirus, rabies, dengue, HEV, HCV, and RSV). A highlight of the chemistry was the preparation of prodrugs for nucleotide triphosphates as this opens a door to new options. The third mini-symposium emphasized how research work in the antiviral area is continuing to expand and needs to do so with a sense of urgency. Although this meeting report covers only a few of the presentations, it aims to illustrate the great diversity of topics discussed at ICAR, bringing together knowledge and expertise from the whole spectrum of antiviral research.